Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2Phase NA 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 22CNS 8Thoracic 5Sarcoma 5Gynecologic 5Gastrointestinal 5Lymphoid 4Head & Neck 3Tumor-Agnostic 2Other hematologic neoplasm 1Dermatologic 1

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 46Paclitaxel 46Gemcitabine 41Carboplatin 37Docetaxel 35Bevacizumab 27Cisplatin 25Irinotecan 22Nivolumab 20Fluorouracil 20Erlotinib Hydrochloride 18Pemetrexed 17Capecitabine 17Sorafenib 16Magnetic Resonance Spectroscopy 16Cetuximab 16Afatinib 16Leucovorin 15regorafenib 14olaparib 13Specimen Handling 13Oxaliplatin 13trametinib 12Biopsy 12130-nm albumin-bound paclitaxel 11eribulin 10atezolizumab 10epothilone B 9Radiotherapy 9Midazolam 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × ribociclib × Tumor-Agnostic × Clear all
NCT03237390 2023-01-05

Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

Mayo Clinic

Phase 1 Completed
43 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01898845 2020-12-19

A Phase I Study of LEE011 in Asian Patients

Novartis

Phase 1 Completed
17 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡